The hardware and bandwidth for this mirror is donated by METANET, the Webhosting and Full Service-Cloud Provider.
If you wish to report a bug, or if you are interested in having us mirror your free-software or open-source project, please feel free to contact us at mirror[@]metanet.ch.
Extension to 'xpose' to support 'nlmixr2'. Provides functions to import 'nlmixr2' fit data into an 'xpose' data object, allowing the use of 'xpose' for 'nlmixr2' model diagnostics.
| Version: | 0.4.0 |
| Depends: | R (≥ 3.2), xpose (≥ 0.4.2) |
| Imports: | ggplot2 (≥ 2.2.1), dplyr (≥ 0.7.4), tibble (≥ 2.0.0), stringr (≥ 1.2.0), tidyr (≥ 0.7.2), magrittr (≥ 1.5), methods (≥ 3.4.1), vpc (≥ 1.0.2), crayon, rlang, nlmixr2est |
| Suggests: | readr, nlmixr2 |
| Published: | 2022-06-08 |
| DOI: | 10.32614/CRAN.package.xpose.nlmixr2 |
| Author: | Justin Wilkins [aut, cre, cph], Matthew Fidler [aut, cph], Benjamin Guiastrennec [aut], Andrew C. Hooker [aut], Anna Olofsson [aut, cph], Sebastian Ueckert [aut], Ron Keizer [aut], Kajsa Harling [ctb], Mike K. Smith [ctb], Elodie Plan [ctb], Mats O. Karlsson [aut, cph], Pharmetheus [ctb], Pfizer [ctb], Occams [ctb], Novartis [ctb] |
| Maintainer: | Justin Wilkins <justin.wilkins at occams.com> |
| License: | GPL-2 | GPL-3 [expanded from: GPL (≥ 2)] |
| NeedsCompilation: | no |
| Materials: | README NEWS |
| In views: | Pharmacokinetics |
| CRAN checks: | xpose.nlmixr2 results |
| Reference manual: | xpose.nlmixr2.pdf |
| Package source: | xpose.nlmixr2_0.4.0.tar.gz |
| Windows binaries: | r-devel: xpose.nlmixr2_0.4.0.zip, r-release: xpose.nlmixr2_0.4.0.zip, r-oldrel: xpose.nlmixr2_0.4.0.zip |
| macOS binaries: | r-release (arm64): xpose.nlmixr2_0.4.0.tgz, r-oldrel (arm64): xpose.nlmixr2_0.4.0.tgz, r-release (x86_64): xpose.nlmixr2_0.4.0.tgz, r-oldrel (x86_64): xpose.nlmixr2_0.4.0.tgz |
| Reverse imports: | nlmixr2rpt |
| Reverse suggests: | shinyMixR |
Please use the canonical form https://CRAN.R-project.org/package=xpose.nlmixr2 to link to this page.
These binaries (installable software) and packages are in development.
They may not be fully stable and should be used with caution. We make no claims about them.